Source: BEFREE

Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE In multivariate analysis, ERCC-1 expression, T-stage, N-stage and tumor subsite are predictive factors for LRF; T-stage and nodal recurrence for OS; stage and treatment response for PFS. 31612639

2020

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE ERCC1 gene expression is significantly related to tumor stage and prognosis in resected ESCC patients from Asian countries. 31713119

2019

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE First-line FOLFIRI-BV and mFOLFOX6-BV had comparable PFS and OS, similar to results in patients with high baseline tumor ERCC1 levels. 30224341

2019

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. 30589644

2019

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE High ERCC1 expression was found in 47.3% patients, and was correlated with higher TNM (p = 0.021), tumor enlargement (p = 0.002), positive lymph nodes (p = 0.001), positive distant metastasis (p = 0.005), and higher relative risk of death (p < 0.001). 31521181

2019

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE In addition, low ERCC1/low XPF (p = 0.003) or low ERCC1/low PARP1 (p = 0.0001) tumors was also linked to better PFS compared to high ERCC1/high XPF or high ERCC1/high PARP1 tumors. 30797591

2019

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 GeneticVariation BEFREE Higher rates of low ERCC1 (35.6 vs. 20.3%, P = 0.0105), RRM1 (23.3 vs. 13.0%, P = 0.0437), STMN1 (72.2 vs. 42.8%, P = 0.0000) and high VEGFR2 (34.4 vs. 18.8%, P = 0.0078) mRNA expression were found in EGFR-mutated tumors, suggesting possible benefit from platinum, gemcitabine, taxanes or VEGFR2 inhibitors. 29948972

2019

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE While enhanced sPD-L1 was associated with residual tumor burden (<i>p</i> = 0.022), reduced sPD-L2 levels were related to platinum-resistance (<i>p</i> < 0.01) and the presence of ERCC1+ CTCs (<i>p</i> < 0.0001). 31681568

2019

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE We retrospectively analyzed tumor tissue of 72 patients using immunohistochemistry to assess the expression of ERCC1. 29905882

2018

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE Our results suggest that two or three negative expressions of p53, p53R2, and ERCC1 in biopsy specimens of primary tumors were associated with a favorable response to CRT for ESCC. 29188501

2018

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE Our findings provided evidence that both blood and tumor tissue MGMT and ERCC1 methylation were associated with cancer rectum. 29080834

2018

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE Multivariate analysis data revealed that ERCC1 and survivin protein expression were independent predictors of overall survival of ESCC patients after chemotherapy and/or radiotherapy (P < .05).ERCC1 overexpression is an important phenotype that is associated with ESCC lymph node metastasis and advanced tumor clinical stages. 30075571

2018

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE We hypothesized that ERCC1 expression and tumour infiltrating lymphocytes (TILS) are induced by chemotherapy in HGSOC, which may be prognostically useful. 30194007

2018

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer. 28388557

2017

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE The results of the present study suggest that ERCC1 expression is an important prognostic indicator for NSCLC, particularly for patients with stage II-III tumors who receive systematic platinum-based adjuvant chemotherapy. 28927101

2017

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE High ERCC1 expression was strongly associated with the presence of genomic alterations and expression levels increased with the number of deletions present in the tumor. 28747165

2017

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE Excision repair cross-complementation group 1 (ERCC1) is a key component in DNA repair mechanisms and may influence the tumor DNA-targeting effect of the chemotherapeutic agent oxaliplatin. 28259288

2017

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE In multivariate analysis performance status (PS), stage of the disease and ERCC1-mRNA expression were independent prognostic factors for EFS whereas tumor histology and stage of the disease were independent factors for OS. 28088319

2017

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE A multivariate logistic regression analysis indicated that pathological responses were significantly associated with tumors with low ERCC1 expression (P = 0.016) and with tumors with high BRCA1 expression (P = 0.030). 27130464

2017

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE High expression of ERCC1 was observed in 33 cases (14.7%) and was statistically associated with lower T stage (P=0.005), lower tumor size (P=0.001), no lymph node metastasis (P=0.044) and no lymphovascular invasion (LVI; P=0.004). 28943968

2017

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 GeneticVariation BEFREE ERCC1 Lys259Thr (rs735482), ERCC2 Lys751Gln (rs13181), ERCC5 His46His C>T (rs1047768), XRCC1 Arg399Gln (rs25487), TP53 Arg72Pro (rs1042522) and MDM2 309T>G (rs2279744) were analyzed on tumor DNA. 28351583

2017

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE Thus, pretreatment ERCC1 expression status can be used to predict tumor response and survival of patients with recurrent or metastatic uterine cervical cancer receiving platinum-based chemotherapy. 29390553

2017

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 Biomarker BEFREE The relative mRNA levels of seven genes including ERBB2, MET, VEGFA, EREG, AREG, PTEN and ERCC1 between tumour (T) and non-tumour (NT) tissue sections were analysed by quantitative real-time PCR. 27002940

2016

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE ERCC1 expression, evaluated by techniques such as immunohistochemistry, has been associated with clinical response; ERCC1<sup>+</sup> tumors are more resistant to cisplatin treatment than are ERCC1<sup>-</sup> tumors. 27610644

2016

Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.400 AlteredExpression BEFREE The ERCC1 expression state did not significantly vary between patient groups according to sex, age, primary tumor site, and tumor and node stage. 27165214

2016